| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/18/2008 | WO2008108689A3 Mix for identification test in the process of quality control of the medicine 'glycine tablets for sublingual applying 0,1g' methods of its preparation and identity evaluation in the process of quality control of the aforementioned medicine |
| 12/18/2008 | WO2008104942A3 Muscarinic receptor antagonists |
| 12/18/2008 | WO2008103574A3 Peroxisome proliferator activated receptor modulators |
| 12/18/2008 | WO2008100977A3 Carbamates therapeutic release agents as amidase inhibitors |
| 12/18/2008 | WO2008100457A3 Functionally selective alpha2c adrenoreceptor agonists |
| 12/18/2008 | WO2008099068B1 Liquid anhydrous composition to be incorporated into the drinking water of cattle |
| 12/18/2008 | WO2008097927A3 Treatment and prevention of neurodegenerative diseases using gene therapy |
| 12/18/2008 | WO2008094575A3 1-h-pyrazolo(3,4b)pyrimidine derivatives and their use as modulators of mitotic kinases |
| 12/18/2008 | WO2008094510A3 Methods of modulating immune function |
| 12/18/2008 | WO2008089201A3 Heterocyclic-substituted piperidine as orl-1 ligands |
| 12/18/2008 | WO2008088358A3 Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases |
| 12/18/2008 | WO2008087654A3 PIPERIDINES AS INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 |
| 12/18/2008 | WO2008087491A3 Method for treating or preventing symptoms of hormonal variations |
| 12/18/2008 | WO2008083174A3 Compositions and methods for the treatment of infections and tumors |
| 12/18/2008 | WO2008082373A3 Pharmaceutical formulations comprising lipase inhibitor |
| 12/18/2008 | WO2008080056A3 Pyridazinones and furan-containing compounds |
| 12/18/2008 | WO2008079339A3 Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections |
| 12/18/2008 | WO2008076862A3 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors |
| 12/18/2008 | WO2008070439A3 Novel bace1 interacting proteins and uses thereof |
| 12/18/2008 | WO2008070310A3 Method to enhance tissue regeneration |
| 12/18/2008 | WO2008067560A3 Compositions and methods of sphingosine kinase inhibitors for use thereof in cancer therapy |
| 12/18/2008 | WO2008067390A3 Metabolites of 5-fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl} quinoline and methods of preparation and uses thereof |
| 12/18/2008 | WO2008067054A3 Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment-resistant strains of head lice |
| 12/18/2008 | WO2008063346A3 IL-14α RNA INHIBITORS AND ANTIBODIES TO IL-14α FOR TREATMENT OF AUTOIMMUNE DISEASES AND LYMPHOMAS |
| 12/18/2008 | WO2008057599A3 Methods for the treatment of abeta related disorders and compositions therefor |
| 12/18/2008 | WO2008053356A3 Immediate release oxymorphone compositions and methods of using same |
| 12/18/2008 | WO2008048867A3 Bicyclic heteroaromatic compounds |
| 12/18/2008 | WO2008043072A3 Cd80 antagonists for treating neoplastic disorders |
| 12/18/2008 | WO2008037484A3 Formulations comprising cyclic compounds |
| 12/18/2008 | WO2008036139A3 Inhibitors of mshc and homologs thereof, and methods of identifying same |
| 12/18/2008 | WO2008033764A3 Quinazolinone and isoquinolinone acetamide derivatives |
| 12/18/2008 | WO2008031888A3 Condensed pyrimidinones active on glutamatergic receptors |
| 12/18/2008 | WO2008028065A3 Sirt activation in managing heart failure |
| 12/18/2008 | WO2008021666A3 Stable liquid levetiracetam compositions and methods |
| 12/18/2008 | WO2008021441A3 Surface sanitizer |
| 12/18/2008 | WO2008016968A3 Non-flushing niacin analogues, and methods of use thereof |
| 12/18/2008 | WO2008016686A3 Enhanced broad-spectrum uv radiation filters and methods |
| 12/18/2008 | WO2008016682A3 Aryl vinyl sulfides, sulfones, sulfoxides and sulfonamides, derivatives thereof and therapeutic uses thereof |
| 12/18/2008 | WO2008013988A3 Method of treating a condition associated with phosphorylation of task-1 |
| 12/18/2008 | WO2008013823A3 Co-crystals of (2r-trans)-6-chloro-5-[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n,1-trimethyl-alpha-oxo-1h-indole-3-acetamide |
| 12/18/2008 | WO2008013782A3 Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists |
| 12/18/2008 | WO2007143676A3 Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
| 12/18/2008 | WO2007130581A3 Compositions and methods for psychiatric conditions and cognition enhancement |
| 12/18/2008 | WO2007127137B1 Disubstituted aniline compounds |
| 12/18/2008 | WO2007124355A3 Vascular endothelial receptor specific inhibitors |
| 12/18/2008 | WO2007124169A3 Compositions and methods for transient receptor potential vanilloid (trpv) channel mediated treatments |
| 12/18/2008 | WO2007109698A3 Novel formulations |
| 12/18/2008 | WO2007103540A3 Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries |
| 12/18/2008 | WO2007100795A3 Combinations comprising a histone deacetylase inhibiting agent and a nuclear hormone receptor ligand for treating cardiovascular conditions |
| 12/18/2008 | WO2007098060A3 Methods and agents for modulating an immune response |
| 12/18/2008 | WO2007092436A3 Compounds for treating inflammatory disorders, demyelinating disorders and cancers |
| 12/18/2008 | WO2007078808A3 Method for isolating (r)-tofisopam |
| 12/18/2008 | WO2007075487A3 Substituted aromatic heterocyclic compounds as fungicides |
| 12/18/2008 | WO2007062148A3 Chemical compounds |
| 12/18/2008 | WO2006118665A3 Method for reducing levels of disease associated proteins |
| 12/18/2008 | WO2006041800A3 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated kv1.3 potassium channel |
| 12/18/2008 | WO2005113478A3 Novel anthraquinones and process for the preparation and method of use thereof |
| 12/18/2008 | WO2003024455A8 Stent coated with a sustained-release drug delivery and method for use thereof |
| 12/18/2008 | US20080313753 Compositions and Methods for Improving Heart Function |
| 12/18/2008 | US20080312462 Process for the manufacture of HMG-CoA reductase inhibitory mevalonic acid derivatives |
| 12/18/2008 | US20080312449 New Compounds |
| 12/18/2008 | US20080312438 -(2-Aminopyrid-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for immunoglobulins IgE and IgG antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis, multiple sclerosis |
| 12/18/2008 | US20080312434 Process for imidazo [4,5-c] pyridin-4-amines |
| 12/18/2008 | US20080312417 Ucp5 |
| 12/18/2008 | US20080312339 Fluorine-substituted alkyl phenol compounds and their uses |
| 12/18/2008 | US20080312338 Formulation |
| 12/18/2008 | US20080312337 Anticancer Composition Comprising Obovatol or Obovatal |
| 12/18/2008 | US20080312336 Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder |
| 12/18/2008 | US20080312335 Liver protection compounds of the cyclohexenone type from antrodia camphorata |
| 12/18/2008 | US20080312334 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone; to treat systemic lupus erythematosus; won't induce uncomfortable side effects, toxicity or complications |
| 12/18/2008 | US20080312333 Agent for Preventing/Ameliorating Life Style-Related Diseases Containing Turmeric Essential Oil Component |
| 12/18/2008 | US20080312332 G Protein-Coupled Receptor Antagonist and Its Use for Preventing and Treating Alzheimer's Disease |
| 12/18/2008 | US20080312331 Method of Treating Dailysis-Induced Hypotension |
| 12/18/2008 | US20080312330 Methods for Reducing Mortality and Morbidity by Postoperative Administration of a Pharmacologic Cardiovascular Agent |
| 12/18/2008 | US20080312329 Nonpeptide Inhibitors of Matrix Metalloproteinases |
| 12/18/2008 | US20080312328 Deuterium-enriched tamsulosin |
| 12/18/2008 | US20080312327 Organic Compositions |
| 12/18/2008 | US20080312326 Method for the Prevention and/or Treatment of Neurodegenerative Diseases Characterized by Administering and Ep1 Receptor Antagonist |
| 12/18/2008 | US20080312325 Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins |
| 12/18/2008 | US20080312324 Treatment of lung cells with histone deacetylase inhibitors |
| 12/18/2008 | US20080312323 Inhibition of TNF-alpha-Initiated Response |
| 12/18/2008 | US20080312322 Organic Compounds |
| 12/18/2008 | US20080312321 Therapeutic substituted cyclopentanes |
| 12/18/2008 | US20080312319 Modulation of Bacterial Quorum Sensing with Synthetic Ligands |
| 12/18/2008 | US20080312318 Deuterium-enriched escitalopram |
| 12/18/2008 | US20080312317 12 membered-ring macrolactam derivatives |
| 12/18/2008 | US20080312316 Chromone Derivatives Useful as Antagonists of Vr1 Receptors |
| 12/18/2008 | US20080312315 Multifunctional Compounds for Forming Crosslinked Biomaterials and Methods of Preparation and Use |
| 12/18/2008 | US20080312314 Alpha crystalline form of strontium ranelate |
| 12/18/2008 | US20080312313 Inhibitors of Ccr9 Activity |
| 12/18/2008 | US20080312312 For treating prostate cancer; (6S,6aR,10aS)-2-Hydroxy-6-(4-hydroxy-phenyl)-6,6a,7,8,10,10a-hexahydro-benzo[c]chromen-9-one; testicular cancer, cardiovascular diseases, neurodegenerative disorders, urinary incontinence, central nervous system disorders, gastrointestinal tract disorders, osteoporosis |
| 12/18/2008 | US20080312311 Crystalline forms of 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine |
| 12/18/2008 | US20080312310 Compounds, Compositions and Methods |
| 12/18/2008 | US20080312309 Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia |
| 12/18/2008 | US20080312308 Substituted acetic acid derivatives |
| 12/18/2008 | US20080312307 Mapk/erk kinase inhibitors |
| 12/18/2008 | US20080312306 Polymorphs, solvates, and hydrate of 5-(4'-fluoro-2'-oxo-1',2'-dihydrospiro[cyclopropane-1,3'-indol]-5'-yl)-1-methyl-1h-pyrrole-2-carbonitrile |
| 12/18/2008 | US20080312305 Imidazoles as Gaba- B Receptor Modulators |
| 12/18/2008 | US20080312304 Topical compositions containing metronidazole |
| 12/18/2008 | US20080312303 Imidazole Derivatives and Their Use for Modulating the Gabaa Receptor Complex |